Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00770731 · ClinicalTrials.gov registry record · Phase 1
Study of Temsirolimus, Topotecan, and Bortezomib
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT00770731: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00770731 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 80 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00770731, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of Torisel (temsirolimus), Hycamtin (topotecan hydrochloride), and Velcade (bortezomib) that can be given, in combination, to patients with advanced cancer that has spread or is unable to be surgically removed. The safety of this drug combination will also be studied.
Primary Outcome
MTD is defined as the highest dose in which the incidence of a dose limiting toxicity (DLT) is \< 33%.
Interventions
- DRUG Velcade (Bortezomib)
- DRUG Torisel (Temsirolimus)
- DRUG Hycamtin (Topotecan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2008-09 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
What the finished NCT00770731 record still lists
NCT00770731 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher).
The record links to 0 conditions, and to 3 interventions - of which Velcade (Bortezomib) is the first listed.
NCT00770731 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00770731 about?
NCT00770731 is a clinical study titled "Study of Temsirolimus, Topotecan, and Bortezomib". The goal of this clinical research study is to find the highest tolerable dose of Torisel (temsirolimus), Hycamtin (topotecan hydrochloride), and Velcade (bortezomib) that can be given, in combination, to patients with advanced cancer that has spread or is unable to be surgically removed. The safety...
What is the current status of trial NCT00770731?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2008-09. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00770731?
The interventions under investigation include: Velcade (Bortezomib) (DRUG), Torisel (Temsirolimus) (DRUG), Hycamtin (Topotecan) (DRUG).
Who is sponsoring clinical trial NCT00770731?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00770731's enrollment target sits among peer trials
80 672nd of 2000 higher than 1,305 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia